Loading…
Employees: 1,106
Size JW Pharmaceutical (001060.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $402M, the 392nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩22,600 on 6 Nov 2026.
Performance Over six months the shares fell 27.6%, against -14.5% for the median peer and -24.5% for the South Korea market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 10.5% over the last twelve months (peer median +8.6%); the operating margin is 13.9% (peer median -11.8%).
Valuation It trades at 6.2× forward earnings against a peer median of 21.7× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.1 points above its cost of capital (6.7% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩821B | ₩775B | ₩719B | ₩749B | ₩684B |
| Revenue growth | — | +8% | -4% | +9% | — |
| Gross profit | ₩388B | ₩359B | ₩323B | ₩336B | ₩288B |
| EBITDA | ₩134B | ₩107B | ₩102B | ₩119B | ₩77.3B |
| Net income | ₩96.0B | ₩58.3B | ₩61.7B | ₩35.1B | ₩30.3B |
| Free cash flow | ₩123B | ₩84.6B | ₩71.1B | ₩59.9B | ₩46.8B |
| Capital expenditure | ₩34.4B | ₩36.1B | ₩28.1B | ₩43.0B | ₩12.4B |
| Total debt | ₩71.8B | ₩54.6B | ₩91.7B | ₩170B | ₩210B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 001060.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.3% | -9.4% | 6th lowest of 21 |
| 6-month return | -27.6% | -14.5% | 7th lowest of 21 |
| Distance from 52-week high | -42.4% | -34.9% | 8th lowest of 21 |
| Revenue growth (TTM) | +10.5% | +8.6% | 8th highest of 18 |
| Operating margin | 13.9% | -11.8% | 3rd highest of 18 |
| Forward P/E | 6.2× | 21.7× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -16.9% | 1.2% | least demanding of 7 |
| Growth delivered (Del g) | +7.2% | +11.7% | 3rd lowest of 7 |
| Hurdle (Req g minus delivered) | -24.1 pp | -14.2 pp | least demanding of 7 |
| ROIC minus cost of capital | +13.1 pp | -7.1 pp | 4th highest of 15 |
| EV / EBITDA | 4.2× | 14.9× | cheapest of 7 |
| Net debt / EBITDA | 0.1× | -0.2× | 4th most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 6.2× | -16.9% | +7.2% |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | n/a | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | n/a | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | n/a | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | n/a | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | n/a | -0.4% | +11.2% |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | n/a | 50.0% | +73.2% |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | n/a | 23.2% | -15.7% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 14.4× | -4.5% | +12.1% |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 54.8× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | n/a | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | n/a | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 203.1× | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 7.6× | -8.8% | +12.8% |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 21.7× | 2.8% | +0.3% |